Table 1 Summary of diagnosis and FLT3 ITD results from patients
Diagnosis | Sample, n | NGS | Fragment analysis | ||
|---|---|---|---|---|---|
FLT3 ITD-positive cases, n (%) | Mean allelic frequency (range) | FLT3 ITD-positive case, n (%) | Mean allelic ratio (range) | ||
Initial | 260 | 61 (23.5) | 0.16 (0.01–0.94) | 61 (23.5) | 1.24 (0.02–28.34) |
AML (APL included) | 236 | 61 (25.8) | 0.16 (0.01–0.94) | 61 (25.8) | 1.24 (0.02–28.34) |
BLL | 5 | 0 | – | 0 | – |
MDS/cytopenia | 13 | 0 | 0 | ||
MPAL | 2 | 0 | – | 0 | – |
Myeloid sarcoma | 3 | 0 | – | 0 | – |
Pure erythroid leukemia | 1 | 0 | – | 0 | – |
Follow-up | 17 | 4 (23.5) | 0.26 (0.01–0.78) | 3 (17.6) | 4.77 (0.62–12.56) |
AML in complete remission | 13 | 0 | – | 0 | – |
AML in relapse/residual blast | 4 | 4 (100.0) | 0.26 (0.01–0.78) | 3 (75.0) | 4.77 (0.62–12.56) |
Total | 277 | 65 (23.5) | 0.15 (0.01–0.94) | 64 (23.1) | 1.39 (0.02–28.34) |